Assess the acceptance and compliance of injectable contraceptive depot medroxyprogestrone acetate


  • Neha Nigam Department of Obstetrics and Gynecology, Government Multispeciality Hospital, Chandigarh, India
  • Jyoti Mishra Department of Obstetrics and Gynecology, Government Multispeciality Hospital, Chandigarh, India
  • Ishwar Rathod Department of Radiation Oncology, Mahatma Gandhi Memorial Medical College, Government Cancer Hospital, Indore, Madhya Pradesh, India



Depot medroxyprogestrone acetate, Injectable contraceptive


Background: The use of safe and effective contraception is the need of the hour in India, with one of the world’s largest and fastest growing population. Assessing the acceptance and compliance of women for temporary contraception DMPA. Acceptance shall be compared between different reproductive age group, different parity and among lactating/non lactating female.

Methods: In this study, 100 women have been taken, those were appropriate within the inclusion criteria for the period of one year. Injection DMPA 150 mg injected intramuscularly every 3 months and used questionnaire method for assessing the acceptance and compliance of women for temporary contraception DMPA.

Results: Injectable contraceptive DMPA is safe, convenient, efficacious and effective long term contraceptive. It is acceptable to women when offered with quality counselling and follow up care. Acceptance of DMPA, was found that there is no need of daily administration of DMPA in 51% of women, 10% women found it’s easy to administer via intramuscular injection, lactating female can breast feed also as it possess no changes in breast milk.

Conclusions: DMPA is highly efficacious, safe and effective method of contraception requiring less frequent dosing and can be used in lactating female. Women who received information on DMPA safety, efficacy and side effects are more likely to continue DMPA use.


National Health Mission Chandigarh family planning/contraception. Available at: Accessed 10 March 2022.

IIPS, Measure DHS, and O. R. C. Macro. "National family health survey (NFHS-2), 1998-99: India." Mumbai: Int Inst Populat Sci, 2000. Available at: Accessed 10 March 2022.

Jejeebhoy SJ, Zavier AJ. Injectable contraceptives: Perspectives and experiences of women and health care providers in India. 2012:1-56.

Vaughan B, Trussell J, Kost K, Singh S, Jones R. Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth. Contracep. 2008;78(4):271-83.

World Health Organisation (WHO). 2010. Medical eligibility criteria for contraceptive use: A WHO family planning cornerstone. Geneva: WHO. 4th ed. WHO data;2010.

Ali MM, Cleland J. Contraceptive switching after method-related discontinuation: levels and differentials. Stud Fam Plann. 2010;41(2):129-33.

Indian Council for Medical Research (ICMR). 2008. Study on 2 Monthly Injectable Contraceptive Norethisterone Enanthate (200mg): Summary Report. Available at: Accessed 18 February 2011.

Parivar Seva Sanstha (PSS). National workshop report on ‘Expanding choices of contraception: injectables-learning from experience’ held at Manesar in October 2004. New Delhi: Parivar Seva Sanstha; 2004.

Family Health International (FHI). Types, availability, and use of Injectables. FHI Briefs, India Brief 3, 2010. Available at: Accessed 10th December 2021.

International Institute for Population Sciences. India National Family Health Survey (NFHS 3), 2005-06. Vol.1. International Institute for Population Sciences, 2007. Available at: Accessed 8th December 2021.

Fonseca M, Deshmukh PY, Kharat D. DMPA: acceptance and compliance in a tertiary care hospital in Mumbai, India. Int J Reprod Contracept Obstet Gynecol. 2017;6(9):3879-81.

Brownell EA, Fernandez ID, Howard CR, Fisher SG, Ternullo SR, Buckley RJ, et al. A systematic review of early postpartum medroxyprogesterone receipt and early breastfeeding cessation: evaluating the methodological rigor of the evidence. Breastfeed Med. 2012;7(1):10-8.

World Health Organization. Task force for epidemiological research on reproductive health, special programme of research, development, and research training in human reproduction, progestogen-only contraceptives during lactation, I: Infant growth. Contraception. 1994;50:35-53.

ACoP BG. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107(6):1453-72.

Rodrigues MI, Kaunitz AM. An evidence of postpartum use of DMPA in breastfeeding women. Contraception. 2009;80(1):4-6.

Kaunitz AM. Injectable depot medroxyprogesterone acetate contraception: an update for US clinicians. Inter J Ferti Women's Med. 1998;43(2):73-83.






Original Research Articles